Hexasodium Phytate

Summary

Hexasodium Phytate (CHEMBL4802218) is a phase-3 clinical-stage unknown.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Unknown
• Clinical trials: 3

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL4802218
Name	Hexasodium Phytate
Type	Unknown
Max phase	3

Also known as: Hexasodium fytate, Hexasodium phytate, Phytate hexasodium, SNF-472, Snf472, SNF472, HEXASODIUM PHYTATE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 3.

Phase distribution

Phase	Trials
PHASE2	2
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04195906	PHASE3	COMPLETED	Phase 3 Study of SNF472 for Calciphylaxis
NCT02790073	PHASE2	COMPLETED	Phase 2 Study With SNF472 in Calciphylaxis Patients
NCT02966028	PHASE2	COMPLETED	Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).